Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Prostate Cancer Prostatic Dis ; 18(4): 325-32, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26260996

ABSTRACT

BACKGROUND: Primary prostate cancers are infiltrated with programmed death-1 (PD-1) expressing CD8+ T-cells. However, in early clinical trials, men with metastatic castrate-resistant prostate cancer did not respond to PD-1 blockade as a monotherapy. One explanation for this unresponsiveness could be that prostate tumors generally do not express programmed death ligand-1 (PD-L1), the primary ligand for PD-1. However, lack of PD-L1 expression in prostate cancer would be surprising, given that phosphatase and tensin homolog (PTEN) loss is relatively common in prostate cancer and several studies have shown that PTEN loss correlates with PD-L1 upregulation--constituting a mechanism of innate immune resistance. This study tested whether prostate cancer cells were capable of expressing PD-L1, and whether the rare PD-L1 expression that occurs in human specimens correlates with PTEN loss. METHODS: Human prostate cancer cell lines were evaluated for PD-L1 expression and loss of PTEN by flow cytometry and western blotting, respectively. Immunohistochemical (IHC) staining for PTEN was correlated with PD-L1 IHC using a series of resected human prostate cancer samples. RESULTS: In vitro, many prostate cancer cell lines upregulated PD-L1 expression in response to inflammatory cytokines, consistent with adaptive immune resistance. In these cell lines, no association between PTEN loss and PD-L1 expression was apparent. In primary prostate tumors, PD-L1 expression was rare, and was not associated with PTEN loss. CONCLUSIONS: These studies show that some prostate cancer cell lines are capable of expressing PD-L1. However, in human prostate cancer, PTEN loss is not associated with PD-L1 expression, arguing against innate immune resistance as a mechanism that mitigates antitumor immune responses in this disease.


Subject(s)
Adaptive Immunity , B7-H1 Antigen/metabolism , Immunity, Innate , Prostatic Neoplasms/immunology , Prostatic Neoplasms/metabolism , Adaptive Immunity/genetics , Anilides/pharmacology , Antineoplastic Agents/pharmacology , B7-H1 Antigen/genetics , Biomarkers , Cell Line, Tumor , Flow Cytometry , Gene Expression Regulation, Neoplastic/drug effects , Humans , Immunity, Innate/genetics , Immunohistochemistry , Interferon-gamma/metabolism , Interferon-gamma/pharmacology , Male , Nitriles/pharmacology , PTEN Phosphohydrolase/genetics , PTEN Phosphohydrolase/metabolism , Prostatic Neoplasms/pathology , Signal Transduction , Tosyl Compounds/pharmacology , Up-Regulation
2.
J Urol ; 177(5): 1736-40, 2007 May.
Article in English | MEDLINE | ID: mdl-17437801

ABSTRACT

PURPOSE: Early prostate cancer antigen is a nuclear matrix protein that was recently shown to be expressed in prostate adenocarcinoma and adjacent benign tissue. Previous studies have demonstrated early prostate cancer antigen expression in benign prostate tissue up to 5 years before a diagnosis of prostate carcinoma, suggesting that early prostate cancer antigen could be used as a potential predictive marker. MATERIALS AND METHODS: We evaluated early prostate cancer antigen expression by immunohistochemistry using a polyclonal antibody (Onconome Inc., Seattle, Washington) on benign biopsies from 98 patients. Biopsies were obtained from 4 groups that included 39 patients with first time negative biopsy (group 1), 24 patients with persistently negative biopsies (group 2), 8 patients with initially negative biopsies who were subsequently diagnosed with prostate carcinoma (group 3) and negative biopsies obtained from 27 cases where other concurrent biopsies contained prostate carcinoma (group 4). Early prostate cancer antigen staining was assessed by 2 of the authors who were blind to the group of the examined sections. Staining intensity (range 0 to 3) and extent (range 1 to 3) scores were assigned. The presence of intensity 3 staining in any of the blocks of a biopsy specimen was considered as positive for early prostate cancer antigen for the primary outcome in the statistical analysis. In addition, as secondary outcomes we evaluated the data using the proportion of blocks with intensity 3 early prostate cancer antigen staining, the mean of the product of staining intensity and staining extent of all blocks within a biopsy, and the mean of the product of intensity 3 staining and extent. RESULTS: Primary outcome analysis revealed the proportion of early prostate cancer antigen positivity to be highest in group 3 (6 of 8, 75%) and lowest in group 2 (7 of 24, 29%, p=0.04 for differences among groups). A relatively higher than expected proportion of early prostate cancer antigen positivity was present in group 1 (23 of 39, 59%). Early prostate cancer antigen was negative in 41% of group 4 who were known to harbor prostate carcinoma. The proportion of early prostate cancer antigen positivity was statistically significantly lower in group 2 than in each of the other groups when compared pairwise. A lower proportion of early prostate cancer antigen positivity was encountered in older archival tissue blocks (p<0.0001) pointing to a potential confounding factor. Corrected for block age, group 3 was the only group to remain statistically significantly different in early prostate cancer antigen positivity compared to the reference group 2. Similar findings were obtained when adjustments for patient age were made and when analysis was based on secondary outcome measurements. CONCLUSIONS: Our study showed a higher proportion of early prostate cancer antigen expression in initial negative prostate biopsy of patients who were diagnosed with prostate carcinoma on subsequent followup biopsies. We found a relatively high proportion of early prostate cancer antigen positivity (59%) in the group with first time negative biopsies and a potential 41% rate of false-negative early prostate cancer antigen staining in benign biopsies from cases with documented prostate carcinoma on concurrent cores. The lower early prostate cancer antigen positivity in cases with older blocks raises the question of a confounding effect of block age. Additional studies on the antigenic properties of early prostate cancer antigen in archival material are required to further delineate the usefulness of early prostate cancer antigen immunostaining on biopsy material.


Subject(s)
Adenocarcinoma/metabolism , Antigens, Neoplasm/biosynthesis , Biomarkers, Tumor/metabolism , Prostatic Neoplasms/metabolism , Adenocarcinoma/pathology , Aged , Biopsy , Diagnosis, Differential , Follow-Up Studies , Humans , Immunohistochemistry , Male , Middle Aged , Prognosis , Prostate-Specific Antigen/blood , Prostatic Neoplasms/pathology , Retrospective Studies , Time Factors
3.
Int J Radiat Biol ; 79(1): 53-60, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12556331

ABSTRACT

PURPOSE: The adenovirus E4orf6 34 kDa protein (E4-34k) is known to disrupt V(D)J recombination as a result of its interaction with the catalytic subunit of cellular DNA-dependent protein kinase (DNA-PK(cs)), a major participant in the repair of DNA double-strand breaks (DSB). Previous studies have shown that cells with disrupted DSB repair and V(D)J recombination due to attenuation of DNA-PK(cs) activity exhibit a radiation-sensitive phenotype. It is not known at present whether the E4-34k protein can also modify cellular response to ionizing radiation. In an attempt to develop a novel gene therapy strategy to modify cellular radiation response, we sought to determine if expression of the adenovirus E4-34k protein resulted in sensitization to clinically relevant doses of ionizing radiation. MATERIALS AND METHODS: In order to minimize potential bias resulting from selection procedures, we performed clonogenic survival assays on DU 145 prostate cancer cells, RKO colorectal cancer cells and 293 kidney cells following transient transfection of E4-34k- and/or E1B-55k-expressing plasmids. Western blots and immunohistochemical analyses were used to demonstrate E4-34k expression within transfected cells. FACS sorting was carried out to enrich cells transfected with a plasmid that expresses both E4-34k and enhanced green fluorescent protein. RESULTS: It is shown that E4-34k expression does not affect cellular radiosensitivity of transiently transfected populations of either DU 145 prostate or RKO colon cancer cell lines. Similarly, the radiosensitivity of human embryonic kidney 293 cells, which constitutively express the E1B-55k protein, was also unaffected. The radiosensitivity of DU 145 cells co-transfected with E4-34k- and E1-55K-expressing plasmids was unchanged, suggesting that the adenovirus E1B-55k protein does not augment any effects E4-34k might have on DNA-PK(cs) activity. CONCLUSIONS: The lack of radiosensitization by E4-34k expression is quite intriguing as it is known that E4-34k interaction with DNA-PK(cs) causes disruption of V(D)J recombination, a process dependent on DSB rejoining. These data suggest that for future studies, preferential targeting of DNA-PK(cs) DSB activity will be required to influence cellular radiosensitivity.


Subject(s)
Adenovirus E4 Proteins/physiology , DNA-Binding Proteins , Protein Serine-Threonine Kinases/metabolism , Radiation Tolerance , Adenovirus E1B Proteins/physiology , Cell Survival/radiation effects , DNA-Activated Protein Kinase , Genes, Immunoglobulin , Humans , Male , Nuclear Proteins , Recombination, Genetic , Transfection , Tumor Cells, Cultured
4.
Cancer Res ; 61(20): 7464-72, 2001 Oct 15.
Article in English | MEDLINE | ID: mdl-11606381

ABSTRACT

CV706 is a prostate-specific antigen (PSA)-selective, replication-competent adenovirus that has been shown to selectively kill human prostate cancer xenografts in preclinical models. To study the safety and activity of intraprostatic delivery of CV706, a Phase I dose-ranging study for the treatment of patients with locally recurrent prostate cancer after radiation therapy was conducted. Twenty patients in five groups were treated with between 1 x 10(11) and 1 x 10(13) viral particles delivered by a real-time, transrectal ultrasound-guided transperineal technique using a three-dimensional plan. The primary end point was the determination of treatment-related toxicity. Secondary objectives included evaluation of the antitumor activity of CV706 and monitoring for other correlates of antineoplastic action. In this study, CV706 was found to be safe and was not associated with irreversible grade 3 or any grade 4 toxicity. No grade >1 alterations in liver function tests associated with CV706 administration were observed. Posttreatment prostatic biopsies and detection of a delayed "peak" of circulating copies of virus provided evidence of intraprostatic replication of CV706. The study defined the timing of CV706 shedding into blood and urine as well as the appearance of circulating Ad5 neutralizing antibodies. Finally, this study documents the serum PSA response of treated patients and reveals a dose response showing that all five patients who achieved a > or =50% reduction in PSA were treated with the highest two doses of CV706. This study represents the first clinical translation of a prostate-specific, replication-restricted adenovirus for the treatment of prostate cancer. Taken together, this study documents that intraprostatic delivery of CV706 can be safely administered to patients, even at high doses, and the data also suggest that CV706 possesses enough clinical activity, as reflected by changes in serum PSA, to warrant additional clinical and laboratory investigation.


Subject(s)
Adenoviridae , Neoplasm Recurrence, Local/therapy , Prostatic Neoplasms/therapy , Adenoviridae/immunology , Aged , Aged, 80 and over , Antibodies, Viral/blood , Biopsy , Humans , Injections, Intralesional , Male , Middle Aged , Neoplasm Recurrence, Local/radiotherapy , Neoplasm Recurrence, Local/virology , Prostate-Specific Antigen/blood , Prostatic Neoplasms/radiotherapy , Prostatic Neoplasms/virology
6.
Cancer Chemother Pharmacol ; 46 Suppl: S67-72, 2000.
Article in English | MEDLINE | ID: mdl-10950151

ABSTRACT

When irradiated and administered intradermally as vaccines, cancer cells engineered to secrete high levels of granulocyte-macrophage colony-stimulating factor (GM-CSF) by gene transfer elicit potent anticancer immune responses in a variety of animal tumor models. Upon vaccination, antigens present in the cancer cells are phagocytosed and processed by skin dendritic cells. These dendritic cells then prime anticancer immune responses by presenting antigenic peptides to T cells. The immune responses generated are capable of eradicating small but lethal cancer cell inocula with minimal toxicity in preclinical animal tumor studies. To develop this vaccination strategy for the treatment of human genitourinary cancers, we have conducted phase I clinical trials using human genitourinary cancer cells as sources of cancer cell antigens. In the first human clinical trial of genetically engineered cancer cell vaccines, a phase I clinical trial of kidney cancer cell vaccines (n = 18), kidney cancer cells were removed at surgery, propagated briefly in vitro, and then genetically modified to secrete high levels of GM-CSF via ex vivo transduction with the retrovirus MFG-GM-CSF. After irradiation, the kidney cancer cells were administered as vaccines to 18 patients with advanced kidney cancers. Vaccine treatment, which caused few side effects, nonetheless appeared to trigger anticancer immune responses manifest as conversion of delayed-type hypersensitivity (DTH) skin responses against irradiated autologous cancer cells after vaccination. Biopsies of vaccine sites yielded findings reminiscent of biopsies from preclinical animal model studies, with evidence of vaccine cell recruitment of dendritic cells, T cells, and eosinophils. One patient with measurable kidney cancer metastases treated at the highest vaccine dose level experienced a partial treatment response. The bioactivity of GM-CSF-secreting autologous cancer cell vaccines was confirmed in a phase I clinical trial for prostate cancer (n = 8). Vaccine cells were prepared from surgically harvested prostate tumors by ex vivo transduction with MFG-GM-CSF in a manner similar to that used for the kidney cancer trial. Vaccine treatment was well tolerated and associated with induction of anticancer immunity as assessed using DTH skin testing. In addition, new antiprostate cancer cell antibodies were detected in serum samples from treated men as a consequence of vaccination. These first clinical trials of GM-CSF-secreting cancer cell vaccines for the treatment of genitourinary cancers have demonstrated both safety and bioactivity, in that very few side effects have been seen and anticancer immune responses have been detected. Future clinical studies will be required to assess vaccine treatment efficacy, refine vaccination dose and schedule, define the appropriate clinical context for the use of such vaccines, and ascertain optimal combinations involving vaccines and other local or systemic anticancer treatments.


Subject(s)
Cancer Vaccines/immunology , Carcinoma, Renal Cell/immunology , Granulocyte-Macrophage Colony-Stimulating Factor/immunology , Kidney Neoplasms/immunology , Prostatic Neoplasms/immunology , Adult , Aged , Antigens, Neoplasm/blood , Antigens, Neoplasm/immunology , Cancer Vaccines/genetics , Cancer Vaccines/therapeutic use , Carcinoma, Renal Cell/therapy , Dose-Response Relationship, Immunologic , Female , Gene Transfer Techniques , Genetic Engineering , Granulocyte-Macrophage Colony-Stimulating Factor/genetics , Granulocyte-Macrophage Colony-Stimulating Factor/metabolism , Humans , Hypersensitivity, Delayed/immunology , Kidney Neoplasms/therapy , Male , Middle Aged , Prostatic Neoplasms/therapy , Retroviridae/genetics
7.
Eur Urol ; 37(3): 350-7, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10720865

ABSTRACT

The cellular origin of carcinosarcoma of the bladder is unknown. We addressed this issue by using microsatellite analysis for loss of heterozygosity (LOH) in both the carcinomatous and sarcomatous components of 6 bladder tumors. We tested 40 microsatellite markers from 19 human chromosomes and compared the genetic alterations between the two separately isolated components. The potential relevance of the E-cadherin pathway was also evaluated by immunohistochemistry. All 6 cases revealed identical LOH on chromosomal arms 9p, 9q, 8p, and 8q, corresponding to relatively early events in bladder carcinogenesis. Discordant losses between two alleles in the remaining chromosomes, associated with progression, were seen in all tumors with a trend toward a higher incidence in the more advanced tumors (N1M1 and N1Mx). E-cadherin was strongly expressed in the carcinomatous components (5 of 6), whereas most of sarcomatous elements displayed absence of the protein product (4 of 6). These results indicate that both the carcinomatous and sarcomatous components of carcinosarcoma are derived from a common stem cell. Downregulation of E-cadherin may define one of the pathways responsible for conversion of epithelial cells to the sarcomatous phenotype.


Subject(s)
Cadherins/analysis , Carcinosarcoma/genetics , Chromosomes, Human, Pair 8 , Chromosomes, Human, Pair 9 , Urinary Bladder Neoplasms/genetics , Urinary Bladder/pathology , Aged , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/pathology , Carcinoma, Transitional Cell/genetics , Carcinoma, Transitional Cell/pathology , Carcinosarcoma/pathology , Female , Humans , Immunoenzyme Techniques , Loss of Heterozygosity , Male , Middle Aged , Neoplastic Stem Cells/pathology , Urinary Bladder Neoplasms/pathology
8.
Cancer Res ; 59(20): 5160-8, 1999 Oct 15.
Article in English | MEDLINE | ID: mdl-10537292

ABSTRACT

Vaccination with irradiated granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting gene-transduced cancer vaccines induces tumoricidal immune responses. In a Phase I human gene therapy trial, eight immunocompetent prostate cancer (PCA) patients were treated with autologous, GM-CSF-secreting, irradiated tumor vaccines prepared from ex vivo retroviral transduction of surgically harvested cells. Expansion of primary cultures of autologous vaccine cells was successful to meet trial specifications in 8 of 11 cases (73%); the yields of the primary culture cell limited the number of courses of vaccination. Side effects were pruritus, erythema, and swelling at vaccination sites. Vaccine site biopsies manifested infiltrates of dendritic cells and macrophages among prostate tumor vaccine cells. Vaccination activated new T-cell and B-cell immune responses against PCA antigens. T-cell responses, evaluated by assessing delayed-type hypersensitivity (DTH) reactions against untransduced autologous tumor cells, were evident in two of eight patients before vaccination and in seven of eight patients after treatment. Reactive DTH site biopsies manifested infiltrates of effector cells consisting of CD45RO+ T-cells, and degranulating eosinophils consistent with activation of both Th1 and Th2 T-cell responses. A distinctive eosinophilic vasculitis was evident near autologous tumor cells at vaccine sites, and at DTH sites. B-cell responses were also induced. Sera from three of eight vaccinated men contained new antibodies recognizing polypeptides of 26, 31, and 150 kDa in protein extracts from prostate cells. The 150-kDa polypeptide was expressed by LNCaP and PC-3 PCA cells, as well as by normal prostate epithelial cells, but not by prostate stromal cells. No antibodies against prostate-specific antigen were detected. These data suggest that both T-cell and B-cell immune responses to human PCA can be generated by treatment with irradiated, GM-CSF gene-transduced PCA vaccines.


Subject(s)
Antigens, Neoplasm/immunology , Cancer Vaccines/immunology , Granulocyte-Macrophage Colony-Stimulating Factor/genetics , Prostatic Neoplasms/therapy , Vaccines, Synthetic/immunology , B-Lymphocytes/immunology , Gene Transfer Techniques , Granulocyte-Macrophage Colony-Stimulating Factor/metabolism , Humans , Hypersensitivity, Delayed/etiology , Male , Middle Aged , Prostatic Neoplasms/immunology , Prostatic Neoplasms/pathology , T-Lymphocytes/immunology , Vaccination
9.
Biochemistry ; 31(43): 10491-501, 1992 Nov 03.
Article in English | MEDLINE | ID: mdl-1420166

ABSTRACT

We previously reported, using a coimmunoprecipitation assay, that the B form (PR-B) of the human progesterone receptor from T47D human breast cancer cells dimerizes in solution with the A receptor (PR-A) and that the extent of dimerization correlates with receptor binding activity for specific DNA sequences [DeMarzo, A.M., Beck, C.A., Oñate, S.A., & Edwards, D.P. (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 72-76]. This suggested that solution dimerization is an intermediate step in the receptor activation process. The present study has tested the effects of the progesterone antagonist RU486 on solution dimerization of progesterone receptors (PR). As determined by the coimmunoprecipitation assay, RU486 binding did not impair dimerization of receptors; rather, the antagonist promoted more efficient solution dimerization than the progestin agonist R5020. This enhanced receptor dimerization correlated with a higher DNA binding activity for transformed receptors bound with RU486. RU486 has been shown previously to produce two other alterations in the human PR when compared with R5020. PR-RU486 complexes in solution exhibit a faster sedimentation rate (6 S) on salt-containing sucrose density gradients than PR-R5020 complexes (4 S), and PR-DNA complexes have a faster electrophoretic mobility on gel-shift assays in the presence of RU486. We presently show that the 6 S PR-RU486 complex is a receptor monomer, not a dimer. The increased sedimentation rate and increased mobility on gel-shift assays promoted by RU486 were also observed with recombinant PR-A and PR-B separately expressed in insect cells from baculovirus vectors. These results suggest that RU486 induces a distinct conformational change both in PR monomers in solution and in dimers bound to DNA. We also examined whether conformational changes in PR induced by RU486 would prevent a PR polypeptide bound to RU486 from heterodimerization with another PR polypeptide bound to R5020. To evaluate this, PR-A and PR-B that were separately bound to R5020 or RU486 in whole cells were mixed in vitro. PR-A-RU486 was capable of dimerization with PR-B-R5020, and this was demonstrated for heterodimers both formed in solution and bound to specific DNA. The capability to form heterodimers in vitro raises the possibility that the antagonist action of RU486 in vivo could in part be imposed in a dominant negative fashion through heterodimerization between one receptor subunit bound to an agonist and another bound to RU486.


Subject(s)
Mifepristone/pharmacology , Receptors, Progesterone/drug effects , Baculoviridae/genetics , Biopolymers , Breast Neoplasms/chemistry , DNA-Binding Proteins/metabolism , Humans , Mifepristone/metabolism , Precipitin Tests , Promegestone/metabolism , Promegestone/pharmacology , Receptors, Progesterone/metabolism , Recombinant Proteins/drug effects , Tumor Cells, Cultured
10.
Steroids ; 56(5): 271-8, 1991 May.
Article in English | MEDLINE | ID: mdl-1652169

ABSTRACT

Mammalian progesterone receptors activated by hormone binding in nuclei of intact cells exhibit substantially higher binding activity for specific DNA sequences than receptors bound with hormone and activated in cell-free cytosol. Differences in DNA-binding activity occur despite the fact that both activated receptor forms sediment at 4S on sucrose gradients and are apparently dissociated from the heat shock protein 90. This suggests that hormone-induced release of heat shock protein 90 from receptors is necessary, but not sufficient for maximal activation of DNA binding. This report is a review of studies from our laboratories that have examined the role of receptor interaction with other nuclear protein factor(s), and receptor dimerization in solution, as additional regulatory steps involved in the process of receptor activation and binding to specific gene sequences.


Subject(s)
DNA, Viral/metabolism , DNA-Binding Proteins/metabolism , Receptors, Progesterone/metabolism , Base Sequence , Blotting, Western , Electrophoresis, Polyacrylamide Gel , Hormones/metabolism , Humans , Mammary Tumor Virus, Mouse/genetics , Molecular Sequence Data , Nuclear Proteins/physiology , Receptors, Progesterone/isolation & purification , Regulatory Sequences, Nucleic Acid , Tumor Cells, Cultured
11.
Proc Natl Acad Sci U S A ; 88(1): 72-6, 1991 Jan 01.
Article in English | MEDLINE | ID: mdl-1986383

ABSTRACT

In this study we have demonstrated that dimerization of mammalian progesterone receptors (PR) occurs in the absence of DNA. A specific immune coisolation assay was performed on extracts of T-47D human breast cancer cells with a monoclonal antibody specific for the full-length B form of progesterone receptor (PR-B). This resulted in coisolation of significant amounts of truncated form-A receptors (PR-A), indicating the presence of stable PR-A.PR-B dimers in solution. A positive correlation was observed between the ability of different receptor forms to oligomerize in solution and their ability to bind to specific DNA sequences. The ability to form stable PR-A.PR-B oligomers in the absence of DNA was also found to correlate with release of 90-kDa heat shock protein (hsp90) from the unactivated PR complex. These results support the hypothesis that dimerization in the absence of DNA is an important mechanism controlling receptor DNA-binding function and that hsp90 release may be a key step regulating dimerization. This suggests that hsp90 may function to repress DNA-binding activity indirectly by blocking receptor dimerization.


Subject(s)
DNA, Neoplasm/metabolism , Heat-Shock Proteins/metabolism , Receptors, Progesterone/metabolism , Base Sequence , Breast Neoplasms , Cell Line , Cell Nucleus/metabolism , Cytosol/metabolism , Humans , Kinetics , Macromolecular Substances , Models, Biological , Molecular Sequence Data , Molecular Weight , Oligonucleotide Probes , Receptors, Progesterone/genetics , Receptors, Progesterone/isolation & purification
12.
Bone ; 9(4): 235-41, 1988.
Article in English | MEDLINE | ID: mdl-3166840

ABSTRACT

Although it is generally acknowledged that matrix vesicles and alkaline phosphatase are required for cartilage calcification, their precise role in initiation or propagation of mineralization remains controversial. We have investigated this problem in a neoplastic model of chondrogenesis, the Swarm rat chondrosarcoma. During serial transplantation these malignant chondrocytes fail to undergo terminal differentiation and do not calcify. To facilitate the study of maturational events in this neoplasm we have developed an intraperitoneal model which grows as discrete free floating tumor nodules. The youngest cells are those on the exterior and maturation progresses towards the center. Ultrastructural examination of the tumor reveals the presence of numerous matrix vesicles in the interterritorial matrix of immature and mature cells. Histochemical localization of alkaline phosphatase reveals a distribution of enzyme activity which varies with the state of maturation of the cells. The most immature cells express large amounts of enzyme on their plasmalemma and in inter-territorial matrix vesicles. The older cells lose membrane activity but maintain activity in their matrix vesicles. These results suggest that while matrix vesicles and/or alkaline phosphatase may be necessary for calcification to proceed, their mere presence is by itself insufficient to initiate or maintain the process.


Subject(s)
Alkaline Phosphatase/analysis , Cartilage/ultrastructure , Chondrosarcoma/ultrastructure , Osteogenesis , Animals , Cartilage/metabolism , Chondrosarcoma/metabolism , Extracellular Matrix/ultrastructure , Histocytochemistry , Rats , Rats, Inbred Strains
SELECTION OF CITATIONS
SEARCH DETAIL
...